ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "scleroderma and systemic sclerosis"

  • Abstract Number: 1811 • 2013 ACR/ARHP Annual Meeting

    Validation Of The ICD-CM-9 Code For Systemic Sclerosis Using Updated ACR/EULAR Classification Criteria

    Aaliya Yaqub1, Lorinda Chung2, David Fiorentino3 and Eswar Krishnan4, 1Stanford Univ Medical Center, Stanford, CA, 2Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, 3Dermatology, Stanford University School of Medicine, Redwood City, CA, 4Medicine, Stanford University, Palo Alto, CA

    Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease associated with substantial morbidity.  Epidemiologic studies using large administrative databases often rely on the accuracy of…
  • Abstract Number: 1745 • 2013 ACR/ARHP Annual Meeting

    Prediction Of Pulmonary Complications In Systemic Sclerosis – Model Development and Validation

    Svetlana I. Nihtyanova1, Benjamin E. Schreiber2, Voon H. Ong3, John G. Coghlan4, Athol U. Wells5 and Christopher P. Denton6, 1Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, 2Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, 3Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom, 4National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom, 5Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom, 6Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom

    Background/Purpose:  Pulmonary complications contribute substantially to systemic sclerosis (SSc) associated morbidity and are the most frequent disease-related cause of death. We explore predictors of clinically…
  • Abstract Number: 1746 • 2013 ACR/ARHP Annual Meeting

    Pericardial Effusions Are Not a Poor Prognostic Factor In Systemic Sclerosis Patients With Pulmonary Hypertension

    Elana J. Bernstein1, Jessica K. Gordon2, Wei-Ti Huang3 and Virginia D. Steen4, 1Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Biostatistics, Hospital for Special Surgery, New York, NY, 4Department of Rheumatology, Georgetown University Medical Center, Washington, DC

    Background/Purpose: Pulmonary hypertension (PH) (defined as a mean pulmonary arterial pressure ≥ 25 mmHg on right heart catheterization) is a leading cause of death in…
  • Abstract Number: 822 • 2013 ACR/ARHP Annual Meeting

    Inhibition Of Casein Kinase II Reduces TGFβ Induced Fibroblast Activation and Ameliorates Experimental Fibrosis

    Yun Zhang, Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany

    Background/Purpose: Casein kinase-2 (CK2) is a highly conserved serine/threonine kinase. CK2 is a tetramer composed of 2 catalytic subunits (α or α’) and 2 β…
  • Abstract Number: 688 • 2013 ACR/ARHP Annual Meeting

    Minimal Clinically Important Investigations In Systemic Sclerosis

    Jessica Meijs1, Anne A. Schouffoer1, Nina Ajmone Marsan2, Maarten K. Ninaber3 and Tom W.J. Huizinga1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Cardiology, Leiden University Medical Center, Leiden, Netherlands, 3Pulmonology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: The optimal management of Systemic Sclerosis (SSc) is a challenge due to the complexity of early diagnosis and identification of patients who are at…
  • Abstract Number: 674 • 2013 ACR/ARHP Annual Meeting

    Systemic Sclerosis Disease Subset Is a Better Predictor Of Long Term Outcome Than Autoantibody Profile

    Svetlana I. Nihtyanova1, Voon H. Ong2 and Christopher P. Denton3, 1Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, 2Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom, 3Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom

    Background/Purpose: Disease subset has been shown to strongly correlate with survival and risk of organ complications in patients with systemic sclerosis (SSc). Nevertheless evidence in…
  • Abstract Number: 675 • 2013 ACR/ARHP Annual Meeting

    Impact Of Male Sex On Survival In Systemic Sclerosis

    Haseena Hussein1, Peter Lee2, Cathy Chau3 and Sindhu R. Johnson4, 1Medicine, Toronto Scleroderma Research Program, Mount Sinai Hospital, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 2Lebovic Bldg, Mt. Sinai Hospital, Toronto, ON, Canada, 3Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 4Medicine, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada

    Background/Purpose: Systemic sclerosis (SSc) has a female predominance with a female-to-male ratio of 3:1. Sex differences have been seen in many autoimmune diseases; however, little…
  • Abstract Number: 680 • 2013 ACR/ARHP Annual Meeting

    Diastolic Dysfunction Amongst Autoantibody Subgroups Of Patients With Diffuse Scleroderma

    Cory Perugino1, John Stephens2, Colin O'Rourke3 and Soumya Chatterjee4, 1Internal Medicine, Cleveland Clinic, Cleveland, OH, 2Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, 3Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, 4Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Scleroderma or systemic sclerosis (SSc) is an autoimmune disease characterized by microangiopathy, tissue hypoxia, and fibrosis. At least seven different autoantibodies have been identified…
  • Abstract Number: 2907 • 2013 ACR/ARHP Annual Meeting

    D1398G Variant Of Hepatocyte Growth Factor Receptor – A Potential Biomarker Of Severe Interstitial Lung Disease In African American Scleroderma Patients

    Ilia Atanelishvili1, Tanjina Akter2, Richard M. Silver3 and Galina S. Bogatkevich2, 1Division of Rheumatology & Immunology, Medical University of South Carolina,Charleston,USA, Charleston, SC, 2Department of Rheumatology, Medical University of South Carolina,Charleston,USA, Charleston, SC, 3Div Rheumatology & Immunology, Medical University of South Carolina,Charleston,USA, Charleston, SC

    Background/Purpose: Interstitial lung disease (ILD) is a major complication and leading cause of mortality in scleroderma (SSc, systemic sclerosis). The morbidity and mortality rates in…
  • Abstract Number: 2422 • 2012 ACR/ARHP Annual Meeting

    Sexual Activity and Sexual Functioning Among Women with Systemic Sclerosis Compared to Women From a Population Sample

    Brooke Levis1, Andrea Burri2, Marie Hudson3, Murray Baron4 and Brett D. Thombs5, 1Epidemiology, McGill University, Montreal, QC, Canada, 2Twin Research and Genetic Epidemiology, King's College, London, United Kingdom, 3Jewish General Hospital, McGill University, Montreal, QC, Canada, 4Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, 5Psychiatry, McGill University, Montreal, QC, Canada

    Background/Purpose: Systemic sclerosis (SSc), or scleroderma, is a chronic, multi-system, connective tissue disorder characterized by thickening and fibrosis of the skin and internal organ involvement.…
  • Abstract Number: 2303 • 2012 ACR/ARHP Annual Meeting

    Confirmation of TNIP1 As a Susceptibility Locus for Systemic Sclerosis in a Large Multicentre Study

    Lara Bossini-Castillo1, Jose Ezequiel Martin2, Carmen Pilar Simeon3, Lorenzo Beretta4, Olga Y. Gorlova5, Madelon C. Vonk6, Patricia Carreira7, the Spanish Scleroderma Group8, Annemie Schuerwegh9, Alexandre Voskuyl10, Anna-Maria Hoffmann-Vold11, Roger Hesselstrand12, Annika Nordin13, Claudio Lunardi14, Jaap Van Laar15, Paul Shiels16, Ariane Herrick17, Jane Worthington18, Carmen Fonseca19, Christopher P. Denton19, Shervin Assassi20, Bobby P.C. Koeleman21, Maureen D. Mayes22, T.R.D.J. Radstake23 and Javier Martin1, 1Immunology, Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN-CSIC), Granada, Spain, 2Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, 3Servicio de Medicina Interna, Hospital Valle de Hebron, Barcelona, Spain, 4Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, 5Department of Epidemiology, UT M. D. Anderson Cancer Center, Houston, TX, 6Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 7Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 8Granada, Spain, 9Leids Univ Medisch Centrum, Leiden, Netherlands, 10Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 11Rheumatology, Oslo University Hospital, Oslo, Norway, 12Rheumatology, Lund University, Lund, Sweden, 13Department of Rheumatology, Karolinska Institute, Stockholm, Sweden, 14Department of Medicine, Università degli Studi di Verona, Verona, Italy, 15Rheumatology, Leiden University Hospital, Leiden, Netherlands, 16University of Glasgow, Glasgow, United Kingdom, 17Musculoskeletal Research Group, University of Manchester, Salford, United Kingdom, 18Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 19Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, 20Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 21Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, 22Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 23Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Systemic sclerosis or scleroderma (SSc) is a complex autoimmune disorder that affects the connective tissue causing fibrosis in the skin and different internal organs.…
  • Abstract Number: 2295 • 2012 ACR/ARHP Annual Meeting

    Caveolin-1 Deficiency Induces Spontaneous Endothelial-to-Mesenchymal Transition (EndoMT) in Murine Pulmonary Endothelial Cells in Vitro

    Zhaodong Li1, Peter J. Wermuth2, Bryan Benn2, Michael P. Lisanti3 and Sergio A. Jimenez2, 1Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA, 2Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, 3Jefferson Stem Cell Biology and Regenerative Medicine Center, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA

    Background/Purpose: Recent studies demonstrated that the phenotypic transition of endothelial cells (EC) into activated mesenchymal cells, a process known an endothelial-to-mesenchymal transition (EndoMT), may be…
  • Abstract Number: 1805 • 2012 ACR/ARHP Annual Meeting

    The Pro-Fibrotic Cytokines IL-33 and IL-13 Modulates Dermal Fibrosis Via the A2A Adenosine Receptor

    Ross C. Radusky1, Jessica L. Feig2, Bruce N. Cronstein3, Andrew G. Franks Jr.4 and Edwin SL Chan1, 1Medicine, New York University School of Medicine, New York, NY, 2Medicine. Department of Translational Medicine, New York University School of Medicine, New York, NY, 3Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, 4Dermatology & Medicine (Rheumatology), New York University, New York, NY

    Background/Purpose: We have previously demonstrated that the nucleoside adenosine mediates collagen production and induce dermal fibrosis in in vitro and in vivo models. IL–13 expression…
  • Abstract Number: 1712 • 2012 ACR/ARHP Annual Meeting

    The Submaximal Heart and Pulmonary Evaluation: A Novel Noninvasive Test to Identify Pulmonary Hypertension in Patients with Systemic Sclerosis

    Elana J. Bernstein1, Jessica K. Gordon2, Robert F. Spiera2, Lisa A. Mandl2 and Evelyn M. Horn3, 1Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Cardiology, New York Presbyterian Hospital/Weill Cornell Medical College, New York, NY

    Background/Purpose: Pulmonary hypertension (PH), defined as a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg on right heart catheterization (RHC), is a leading cause of…
  • Abstract Number: 1505 • 2012 ACR/ARHP Annual Meeting

    Inactivation of Tankyrases Ameliorates Canonical Wnt Signaling and Prevents Experimental Fibrosis

    Alfiya Distler1, Lisa Deloch2, Jingang Huang2, Clara Dees2, Neng Yu Lin2, Christian Beyer3, Oliver Distler4, Georg A. Schett5 and Joerg HW Distler1, 1Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 3Department of Internal Medicine 3, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 4Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 5Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: Systemic sclerosis (SSc) is characterized by aberrant activation of fibroblasts with increased release of extracellular matrix components. Canonical Wnt signaling has recently emerged as…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology